search reports
Categories
Categories

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016

Report Code : gdph0503qd
Published Date : 01 December, 2016 | No of Pages: 133

  • Report Description
  • Table of Contents
  • Related Reports
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19
2.4.2 Pfizer Acquires Medivation in Tender Offer 20
2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21
2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21
2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23
3.1.1 Top M&A Deals in Q3 2016 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26
3.2.1 Top Initial Public Offerings in Q3 2016 27
3.2.2 Top Secondary Offerings in Q3 2016 27
3.2.3 Top PIPE Deals in Q3 2016 28
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30
3.3.1 Top Venture Financing Deals in Q3 2016 31
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37
3.4.1 Top Private Equity Deals in Q3 2016 38
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 66
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 68
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2015 - Q3 2016 68
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2015 - Q3 2016 70
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2015 - Q3 2016 73
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 75
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2016 75
7.1.1 Oncology - Deals of the Quarter 76
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2016 79
7.2.1 Central Nervous System - Deals of the Quarter 80
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2016 84
7.3.1 Infectious Disease - Deals of the Quarter 85
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2016 87
7.4.1 Immunology - Deals of the Quarter 88
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2016 90
7.5.1 Metabolic Disorders - Deals of the Quarter 91
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2016 93
7.6.1 Cardiovascular - Deals of the Quarter 94
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2016 97
7.7.1 Gastrointestinal - Deals of the Quarter 98
7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2016 100
7.8.1 Ophthalmology - Deals of the Quarter 101
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2016 103
7.9.1 Respiratory - Deals of the Quarter 104
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2016 107
7.10.1 Dermatology - Deals of the Quarter 108
8 Deal Summary by Geography 111
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2016 111
8.1.1 North America - Deals of the Quarter 112
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2016 115
8.2.1 Europe - Deals of the Quarter 116
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2016 118
8.3.1 Asia-Pacific - Deals of the Quarter 119
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2016 121
8.4.1 Rest of the World - Deals of the Quarter 122
9 Pharmaceuticals & Healthcare, Global, Top Advisors 124
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2015 - Q3 2016 124
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2015 - Q3 2016 126
10 Appendix 128
11 Further Information 130
11.1 Methodology 130
11.2 About GlobalData 131
11.3 Disclosure information 132
11.4 Disclaimer 1321.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 16
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2016 18
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 24
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2016 24
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2015 - Q3 2016 25
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 27
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2016 27
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2016 27
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2016 28
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 29
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 31
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2016 31
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2016 33
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 34
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 38
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2016 38
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 39
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 43
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 45
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 45
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2016 46
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 48
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 51
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 53
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 55
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 57
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2016 57
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2016 58
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2016 58
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 60
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2015 - Q3 2016 62
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 65
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 67
Table 39: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 69
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2015 - Q3 2016 72
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74
Table 45: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 76
Table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 80
Table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 85
Table 48: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 88
Table 49: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 91
Table 50: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 94
Table 51: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 98
Table 52: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 101
Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 104
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 108
Table 55: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 112
Table 56: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 116
Table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 119
Table 58: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 122
Table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 125
Table 60: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 127
Table 61: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q3 2015-Q3 2016 1281.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2016 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2016 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 23
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2015 - Q3 2016 25
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 26
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2015 - Q3 2016 28
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 30
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2016 32
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2016 32
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 33
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 37
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 39
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 40
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 47
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 49
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 50
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 52
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 54
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 61
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 63
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 64
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 66
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 68
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74
Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 75
Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 79
Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 84
Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 87
Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 90
Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 93
Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 97
Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 100
Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 103
Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 107
Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 111
Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 115
Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 118
Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 121
Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 124
Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 126
Market Intel Report Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals
By: GlobalData | Published Date : 01 March, 2016 | No of Pages : 108
Market Intel Report Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016
By: GlobalData | Published Date : 03 June, 2016 | No of Pages : 132
Please select License
Single User Price:$ 1500
Site License Price:$ 3000
Enterprise Price:$ 4500